Long-term medical imaging use in children with central nervous system tumors.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 02 09 2020
accepted: 15 02 2021
entrez: 21 4 2021
pubmed: 22 4 2021
medline: 23 9 2021
Statut: epublish

Résumé

Children with central nervous system (CNS) tumors undergo frequent imaging for diagnosis and follow-up, but few studies have characterized longitudinal imaging patterns. We described medical imaging in children before and after malignant CNS tumor diagnosis. We conducted a retrospective cohort study of children aged 0-20 years diagnosed with CNS tumors between 1996-2016 at six U.S. integrated healthcare systems and Ontario, Canada. We collected computed topography (CT), magnetic resonance imaging (MRI), radiography, ultrasound, nuclear medicine examinations from 12 months before through 10 years after CNS diagnosis censoring six months before death or a subsequent cancer diagnosis, disenrollment from the health system, age 21 years, or December 31, 2016. We calculated imaging rates per child per month stratified by modality, country, diagnosis age, calendar year, time since diagnosis, and tumor grade. We observed 1,879 children with median four years follow-up post-diagnosis in the U.S. and seven years in Ontario, Canada. During the diagnosis period (±15 days of diagnosis), children averaged 1.10 CTs (95% confidence interval [CI] 1.09-1.13) and 2.14 MRIs (95%CI 2.12-2.16) in the U.S., and 1.67 CTs (95%CI 1.65-1.68) and 1.86 MRIs (95%CI 1.85-1.88) in Ontario. Within one year after diagnosis, 19% of children had ≥5 CTs and 45% had ≥5 MRIs. By nine years after diagnosis, children averaged one MRI and one radiograph per year with little use of other imaging modalities. MRI and CT are commonly used for CNS tumor diagnosis, whereas MRI is the primary modality used during surveillance of children with CNS tumors.

Sections du résumé

BACKGROUND
Children with central nervous system (CNS) tumors undergo frequent imaging for diagnosis and follow-up, but few studies have characterized longitudinal imaging patterns. We described medical imaging in children before and after malignant CNS tumor diagnosis.
PROCEDURE
We conducted a retrospective cohort study of children aged 0-20 years diagnosed with CNS tumors between 1996-2016 at six U.S. integrated healthcare systems and Ontario, Canada. We collected computed topography (CT), magnetic resonance imaging (MRI), radiography, ultrasound, nuclear medicine examinations from 12 months before through 10 years after CNS diagnosis censoring six months before death or a subsequent cancer diagnosis, disenrollment from the health system, age 21 years, or December 31, 2016. We calculated imaging rates per child per month stratified by modality, country, diagnosis age, calendar year, time since diagnosis, and tumor grade.
RESULTS
We observed 1,879 children with median four years follow-up post-diagnosis in the U.S. and seven years in Ontario, Canada. During the diagnosis period (±15 days of diagnosis), children averaged 1.10 CTs (95% confidence interval [CI] 1.09-1.13) and 2.14 MRIs (95%CI 2.12-2.16) in the U.S., and 1.67 CTs (95%CI 1.65-1.68) and 1.86 MRIs (95%CI 1.85-1.88) in Ontario. Within one year after diagnosis, 19% of children had ≥5 CTs and 45% had ≥5 MRIs. By nine years after diagnosis, children averaged one MRI and one radiograph per year with little use of other imaging modalities.
CONCLUSIONS
MRI and CT are commonly used for CNS tumor diagnosis, whereas MRI is the primary modality used during surveillance of children with CNS tumors.

Identifiants

pubmed: 33882069
doi: 10.1371/journal.pone.0248643
pii: PONE-D-20-27638
pmc: PMC8059842
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0248643

Subventions

Organisme : NCI NIH HHS
ID : R01 CA185687
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211115
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Neurosurg Anesthesiol. 2014 Oct;26(4):377-86
pubmed: 25144506
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1033-40
pubmed: 19336557
Pediatr Radiol. 2018 Aug;48(9):1324-1336
pubmed: 30078040
Pediatr Blood Cancer. 2013 Aug;60(8):1253-60
pubmed: 23572212
Oncol Res Treat. 2017;40(12):746-750
pubmed: 29183026
Pediatr Radiol. 2016 Jan;46(1):9-20; quiz 6-8
pubmed: 26459011
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Pediatr Radiol. 2011 Sep;41 Suppl 2:505-8
pubmed: 21847730
JAMA Netw Open. 2019 Jul 3;2(7):e197249
pubmed: 31339541
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2716-36
pubmed: 25192704
Pediatr Blood Cancer. 2013 Apr;60(4):543-9
pubmed: 23281199
J Clin Oncol. 2015 Sep 20;33(27):3055-64
pubmed: 26304891
Pediatr Blood Cancer. 2018 Nov;65(11):e27311
pubmed: 30009501
JAMA. 2019 Sep 3;322(9):843-856
pubmed: 31479136
J Natl Cancer Inst. 2014 Sep 22;106(11):
pubmed: 25249551
J Clin Anesth. 2014 Nov;26(7):551-6
pubmed: 25439418
J Pediatr Hematol Oncol. 2018 Jan;40(1):36-42
pubmed: 28697171
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
J Oncol Pract. 2016 Mar;12(3):190-3
pubmed: 26907451
Anesthesiology. 2017 Aug;127(2):227-240
pubmed: 28609302
Arch Pediatr Adolesc Med. 2007 Aug;161(8):798-806
pubmed: 17679663
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Clin Radiol. 2003 Aug;58(8):589-603
pubmed: 12887951

Auteurs

Erin J A Bowles (EJA)

Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, United States of America.

Diana L Miglioretti (DL)

Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, United States of America.
Department of Public Health Sciences, University of California, Davis, Davis, California, United States of America.
University of California Davis Comprehensive Cancer Center, Davis, California, United States of America.

Marilyn L Kwan (ML)

Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America.

Ute Bartels (U)

The Hospital for Sick Children, Toronto, Ontario, Canada.

Adam Furst (A)

Department of Public Health Sciences, University of California, Davis, Davis, California, United States of America.

Stephanie Y Cheng (SY)

ICES, Toronto, Ontario, Canada.

Cindy Lau (C)

ICES, Toronto, Ontario, Canada.

Robert T Greenlee (RT)

Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, Wisconsin, United States of America.

Sheila Weinmann (S)

Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, United States of America.
Center for Integrated Health Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, United States of America.

Emily C Marlow (EC)

Department of Public Health Sciences, University of California, Davis, Davis, California, United States of America.

Alanna K Rahm (AK)

Center for Health Research, Genomic Medicine Institute, Geisinger, Danville, Pennsylvania, United States of America.

Natasha K Stout (NK)

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America.

Wes E Bolch (WE)

Department of Biomedical Engineering, University of Florida, Gainesville, Florida, United States of America.

Mary Kay Theis (MK)

Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, United States of America.

Rebecca Smith-Bindman (R)

Department of Radiology and Biomedical Imaging, Epidemiology and Biostatistics and The Philip R. Lee Institute for Health Policy, University of California, San Francisco, San Francisco, California, United States of America.

Jason D Pole (JD)

The Hospital for Sick Children, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.
Centre for Health Services Research, The University of Queensland, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH